Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maria Ripps from Canaccord Genuity maintained a Buy rating on the stock and has a $68.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Maria Ripps has given her Buy rating due to a combination of factors, including Hims & Hers Health’s impressive financial performance and strategic initiatives. The company reported strong first-quarter results, with revenue and profitability exceeding expectations. Notably, core revenue grew significantly, driven by substantial contributions from GLP-1s and a remarkable increase in subscribers for oral weight loss solutions.
Additionally, Hims & Hers Health’s strategic partnerships and product expansions are promising. The collaboration with Novo Nordisk is expected to broaden their product roadmap, and the company plans to introduce new offerings in areas like low testosterone and menopause support. Despite a modestly lower Q2 guidance, the company maintained its FY25 revenue outlook and increased its profitability forecast, indicating confidence in its long-term growth potential. These factors, combined with the appointment of a former Amazon executive as COO, reinforce the positive outlook for the company’s future performance.
In another report released today, Needham also reiterated a Buy rating on the stock with a $61.00 price target.
HIMS’s price has also changed dramatically for the past six months – from $20.640 to $41.880, which is a 102.91% increase.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue